Form 4: Arteris CFO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Arteris Inc.'s VP and CFO, Nicholas B. Hawkins, sold 3,660 shares of common stock for a weighted average price of $8.6903, executed under a pre-arranged 10b5-1 trading plan.
Summary
- Nicholas B. Hawkins, VP and Chief Financial Officer of Arteris, Inc. (AIP), reported a sale of common stock.
- The transaction involved the disposition of 3,660 shares of common stock.
- The shares were sold at a weighted average price of $8.6903 per share.
- Individual sale prices ranged from $8.51 to $8.83.
- The sale was executed on September 9, 2025.
- Following the transaction, Mr. Hawkins directly beneficially owns 103,898 shares of Arteris common stock.
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Hawkins on June 4, 2025.
Sentiment
Score: 6
Explanation: The sale by a CFO is generally a neutral to slightly negative signal. However, the execution under a pre-arranged 10b5-1 plan mitigates much of the potential negative interpretation, suggesting a planned financial action rather than a reaction to new company developments.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance and not based on recent non-public information, which reduces the negative perception often associated with insider sales.
Negatives
- An insider, specifically the Chief Financial Officer, sold a portion of their holdings, which can sometimes be perceived as a lack of confidence in the company's near-term prospects, despite the 10b5-1 plan.
Risks
- While the sale was pre-planned, a consistent pattern of insider selling by multiple executives could signal potential concerns about future performance or valuation.
Future Outlook
NA
Industry Context
This is a routine insider transaction filing (Form 4) and does not inherently provide broader industry context. Such sales are common for executives managing personal finances or diversifying portfolios, especially when executed under a 10b5-1 plan.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Adoption | The reporting person adopted a Rule 10b5-1 trading plan on June 4, 2025, which allows insiders to set up a pre-scheduled plan for buying or selling company stock to avoid accusations of insider trading. | June 4, 2025 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reported transaction. |
Stakeholder Impact
- Shareholders may view the sale by a key executive with slight caution, although the 10b5-1 plan mitigates concerns about opportunistic selling. The impact is likely minimal given the pre-planned nature.
Key Dates
| Date | Description |
|---|---|
| June 4, 2025 | Date the Rule 10b5-1 trading plan was adopted by Nicholas B. Hawkins. |
| September 9, 2025 | Date of the reported transaction (sale of common stock). |
| September 10, 2025 | Date the Form 4 filing was signed. |
Recommendation
holdA single Form 4 filing detailing a pre-planned insider sale, especially by a CFO, typically does not provide sufficient information to warrant a strong buy or sell recommendation. The 10b5-1 plan suggests a routine financial management decision rather than a signal about the company's immediate prospects. Investors should consider this in the broader context of the company's financial performance and market conditions.
Keywords
Arteris, AIP, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Nicholas B. Hawkins, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.